{"entity":{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","aka":[],"tldr":"Maeve Lowery represents Trinity St James's Cancer Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Maeve Lowery is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Trinity St James's Cancer Institute, its member in Ireland. Ireland's first OECI-accredited Comprehensive Cancer Centre, a partnership between St James's Hospital and Trinity College Dublin. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Trinity St James's Cancer Institute website","url":"http://www.stjames.ie/cancer"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["trinity-st-jamess-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Trinity St James's Cancer Institute to the Organisation of European Cancer Institutes","institutionId":"trinity-st-jamess-cancer-institute","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Trinity St James's Cancer Institute website","url":"http://www.stjames.ie/cancer"}],"papers":[{"title":"OncoKB: A Precision Oncology Knowledge Base","journal":"JCO Precis Oncol","year":2017,"url":"https://doi.org/10.1200/po.17.00011","doi":"10.1200/po.17.00011","note":"Europe PMC author record matched by affiliation"},{"title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","journal":"Lancet Oncol","year":2020,"url":"https://doi.org/10.1016/s1470-2045(20)30157-1","doi":"10.1016/s1470-2045(20)30157-1","note":"Europe PMC author record matched by affiliation"},{"title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","journal":"Lancet Oncol","year":2023,"url":"https://doi.org/10.1016/s1470-2045(23)00515-6","doi":"10.1016/s1470-2045(23)00515-6","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-1354-7606"},"route":"/people/maeve-lowery/","neighbours":{"institution":[{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"},{"id":"trinity-st-jamess-cancer-institute","kind":"institution","name":"Trinity St James's Cancer Institute","route":"/institutions/trinity-st-jamess-cancer-institute/"}],"paper":[{"id":"paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018","kind":"paper","name":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","route":"/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/"}]}}